by Peter Ciszewski | Jun 14, 2018
Roxana Sulica, MD, Associate Professor, Department of Medicine and Director, Pulmonary Hypertension at NYU Langone in New York City discusses some of the emerging tretment options for pulmonary arterial hypertension (PAH). One of these emerging therapies is the...
by Peter Ciszewski | Jun 13, 2018
As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and families say would motivate them for or against participating in such research trials....
by Peter Ciszewski | Jun 12, 2018
Mr. Robert (Bob) E. Ward, Chairman of the Board and Chief Executive Officer of Eloxx Pharmaceuticals provides an overview of his company and it’s focus on cystic fibrosis. Eloxx is a clinical-stage biopharmaceutical company developing novel RNA-modulating...
by Peter Ciszewski | Jun 11, 2018
The Food and Drug Administration (FDA) granted approval to venetoclax for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Approval was based on MURANO...
by Peter Ciszewski | Jun 10, 2018
Editor’s Note: This interview was conducted at #BIO2018. Please pardon the background noise. Chris Garabedian discusses his new compay, Xontogeny, a biotech aggregator with a differentiated business model to support the accelerated development of life...
